logo
book Subscribe to our Magazine
    • Magazine
    • Membership
    • Donate
  • Racial Justice
  • Economic Justice
  • Climate Justice
  • Health Justice
  • Leadership
    • Grassroots Fundraising Journal
  • CONTENT TYPES
  • Podcasts
    • Tiny Spark
    • Women of Color in Power
  • Webinars
    • Free Webinars
    • Premium On-Demand Webinars
  • Membership

Court Documents Highlight Sackler Family Role in Promoting OxyContin Sales

Steve Dubb
January 17, 2019
Share
Tweet
Share
Email
Print
Psiĥedelisto [CC0], from Wikimedia Commons

January 15, 2019; New York Times

Last June, NPQ reported that Massachusetts Attorney General Maura Healey named eight Sackler family members as defendants in a complaint that accused Purdue Pharma of spinning a “‘web of illegal deceit’ to boost profits.” Now, a 312-page document in state court provides new details regarding how that web was constructed.

The descendants of Mortimer and Raymond Sackler, the nation’s 19th-wealthiest family, are, as NPQ has noted, major names in arts philanthropy. Last year, photographer Nan Goldin, herself an opioid addiction survivor, led a museum-based protest action to call attention to the connection and call on the family to make amends. In an article published in the Guardian, NPQ staff also pointed out that the Sacklers have been “generous patrons of medical research at the nation’s leading universities, including Columbia, Cornell, Tufts and Yale.”

As the death toll from opioids in the United States has grown to approach 218,000 (as of year-end 2017), hundreds of states, cities, and tribal governments have filed suit. The Massachusetts suit, however, is unique in making the Sacklers themselves defendants.

Now, as Barry Meier writes in the New York Times, Massachusetts is using previously undisclosed documents to argue that the Sacklers were not just beneficiaries of OxyContin profits, but also architects of many of the deceptive practices of Purdue Pharma. As Meier puts it, the state’s claim is that, “Members of the Sackler family, which owns the company that makes OxyContin, directed years of efforts to mislead doctors and patients about the dangers of the powerful opioid painkiller.”

For example, paragraph 8 of the state’s complaint contends that “Defendants Richard Sackler, Beverly Sackler, David Sackler, Ilene Sackler Lefcourt, Jonathan Sackler, Kathe Sackler, Mortimer Sackler, and Theresa Sackler controlled Purdue’s misconduct. Each of them took a seat on the Board of Directors of Purdue Pharma Inc. Together, they always held the controlling majority of the Board, which gave them full power over both Purdue Pharma Inc. and Purdue Pharma LP. They directed deceptive sales and marketing practices deep within Purdue, sending hundreds of orders to executives and line employees. From the money that Purdue collected selling opioids, they paid themselves and their family billions of dollars.”

Sign up for our free newsletter

Subscribe to the NPQ newsletter to have our top stories delivered directly to your inbox.

By signing up, you agree to our privacy policy and terms of use, and to receive messages from NPQ and our partners.

In particular, emails cited in the complaint show members of the Sackler family engaged deeply in company operations. For example, Richard Sackler, Purdue Pharma president at the time, in 2001 wrote an email that advocated that the company push blame onto the people who had become addicted, writing, “We have to hammer on abusers in every way possible. They are the culprits and the problem. They are reckless criminals.”

Other specific allegations in the complaint include:

  • “In 1997, Richard Sackler, Kathe Sackler, and other Purdue executives determined—and recorded in secret internal correspondence—that doctors had the crucial misconception that OxyContin was weaker than morphine, which led them to prescribe OxyContin much more often, even as a substitute for Tylenol” and advocated taking advantage of that misperception to increase drug sales.
  • In February 2001, when a federal prosecutor reported 59 deaths from OxyContin in a single state, Richard Sackler, who the complaint alleges knew the number was an underestimate, wrote to Purdue executives that, “This is not too bad. It could have been far worse.”
  • From 2007 to 2018, the Sacklers maintained tight control, directing “the company to hire hundreds more sales reps to visit doctors thousands more times. They insisted that sales reps repeatedly visit the most prolific prescribers. They directed reps to encourage doctors to prescribe more of the highest doses of opioids. They studied unlawful tactics to keep patients on opioids longer and then ordered staff to use them…They sometimes demanded more detail than anyone else in the entire company, so staff had to create special reports just for them.”

Much of the report details, blow by blow, instances in which different family members followed up on sales numbers and advised staff regarding marketing tactics. One example appears in paragraph 392 of the complaint:

In January 2013, in what was becoming a yearly ritual, Richard Sackler questioned staff about the drop in opioid prescriptions caused by Purdue sales reps taking time off for the holidays. Richard wasn’t satisfied: “Really don’t understand why this happens. What about refills last week? Was our share up or down?” Staff assured Richard that doctors were “sensitive” to sales rep visits and, as soon as the reps got back into action, they would “boost” opioid prescriptions again.

The impact of the Massachusetts case remains to be seen, but the email correspondence uncovered does make it much harder for the Sackler owners at Purdue Pharma to maintain a position of innocence. “For years,” notes Meier, “Purdue Pharma has sought to depict the Sackler family as removed from the day-to-day operations of the company. The Sacklers, whose name adorns museums and medical schools around the world, are one of the richest families in the United States, with much of their wealth derived from sales of OxyContin. Disclosure of the documents is likely to renew calls for institutions to decline their philanthropic gifts.”—Steve Dubb

Share
Tweet
Share
Email
Print
ABOUT THE AUTHOR
Steve Dubb

Steve Dubb is a senior editor at NPQ, where he directs NPQ’s economic justice program, including NPQ’s Economy Remix column. Steve has worked with cooperatives and nonprofits for over two decades, including twelve years at The Democracy Collaborative and three years as executive director of NASCO (North American Students of Cooperation). In his work, Steve has authored, co-authored and edited numerous reports; participated in and facilitated learning cohorts; designed community building strategies; and helped build the field of community wealth building. Steve is the lead author of Building Wealth: The Asset-Based Approach to Solving Social and Economic Problems (Aspen 2005) and coauthor (with Rita Hodges) of The Road Half Traveled: University Engagement at a Crossroads, published by MSU Press in 2012. In 2016, Steve curated and authored Conversations on Community Wealth Building, a collection of interviews of community builders that Steve had conducted over the previous decade.

More about: Big PharmaManagement and LeadershipNonprofit Newsopioid addiction

Become a member

Support independent journalism and knowledge creation for civil society. Become a member of Nonprofit Quarterly.

Members receive unlimited access to our archived and upcoming digital content. NPQ is the leading journal in the nonprofit sector written by social change experts. Gain access to our exclusive library of online courses led by thought leaders and educators providing contextualized information to help nonprofit practitioners make sense of changing conditions and improve infra-structure in their organizations.

Join Today
logo logo logo logo logo
See comments

NPQ_Spring_2022

You might also like
Salvadoran Foreign Agent Law Threatens Human Rights Movements
Devon Kearney
Healing-Centered Leadership: A Path to Transformation
Shawn A. Ginwright
Into the Fire: Lessons from Movement Conflicts
Ingrid Benedict, Weyam Ghadbian and Jovida Ross
How Nonprofits Can Truly Advance Change
Hildy Gottlieb
The Road to Social Impact: Leveraging Community Power and Institutional Influence
Katherine R. Cooper and Michelle Shumate
2021 by the Numbers
Nonprofit Quarterly

Upcoming Webinars

May 11 & 12, 2 pm ET

Mastering QuickBooks 2022

The How-to Clinic for Nonprofit Bookkeepers for Online QuickBooks Users

Register
You might also like
Salvadoran Foreign Agent Law Threatens Human Rights...
Devon Kearney
Healing-Centered Leadership: A Path to Transformation
Shawn A. Ginwright
Into the Fire: Lessons from Movement Conflicts
Ingrid Benedict, Weyam Ghadbian and Jovida Ross
WOMEN OF COLOR IN POWER
Women of Color in Power

Listen wherever you get your podcasts.

Subscribe
Rep. Ayanna Pressley and Authentic Leadership
Reclaiming Interrupted Lineages

Like what you see?

Subscribe to the NPQ newsletter to have our top stories delivered directly to your inbox.

By signing up, you agree to our privacy policy and terms of use, and to receive messages from NPQ and our partners.

Independent & in your mailbox.

Subscribe today and get a full year of NPQ for just $59.

subscribe
  • About
  • Contact
  • Submissions
  • Advertisers
  • Newsletters
  • Copyright

Subscribe to View Webinars

We are using cookies to give you the best experience on our website.

 

Non Profit News | Nonprofit Quarterly
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.